دورية أكاديمية
أعرض في EDS

Genetic surveillance for monitoring the impact of drug use on Plasmodium falciparum populations.

التفاصيل البيبلوغرافية
العنوان: Genetic surveillance for monitoring the impact of drug use on Plasmodium falciparum populations.
المؤلفون: Ndiaye YD; Dantec Teaching and Research Hospital, Dakar, Senegal. Electronic address: ydndiaye@gmail.com., Hartl DL; Harvard University, Cambridge, MA, USA. Electronic address: dhartl@oeb.harvard.edu., McGregor D; Harvard T.H. Chan School of Public Health, Boston, MA, USA. Electronic address: dmcgregor@hsph.harvard.edu., Badiane A; Cheikh Anta Diop University, Dakar, Senegal. Electronic address: asbadiane@gmail.com., Fall FB; Programme National de Lutte Contre le Paludisme, Senegal. Electronic address: fatybafall@gmail.com., Daniels RF; Harvard T.H. Chan School of Public Health, Boston, MA, USA; The Broad Institute, Cambridge, MA, USA. Electronic address: rdaniels@hsph.harvard.edu., Wirth DF; Harvard T.H. Chan School of Public Health, Boston, MA, USA; The Broad Institute, Cambridge, MA, USA. Electronic address: dfwirth@hsph.harvard.edu., Ndiaye D; Cheikh Anta Diop University, Dakar, Senegal. Electronic address: daouda.ndiaye@ucad.edu.sn., Volkman SK; Harvard T.H. Chan School of Public Health, Boston, MA, USA; The Broad Institute, Cambridge, MA, USA; Simmons University, Boston, MA, USA. Electronic address: svolkman@hsph.harvard.edu.
المصدر: International journal for parasitology. Drugs and drug resistance [Int J Parasitol Drugs Drug Resist] 2021 Dec; Vol. 17, pp. 12-22. Date of Electronic Publication: 2021 Jul 26.
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 101576715 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-3207 (Electronic) Linking ISSN: 22113207 NLM ISO Abbreviation: Int J Parasitol Drugs Drug Resist Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier, 2011-
مواضيع طبية MeSH: Antimalarials*/pharmacology , Antimalarials*/therapeutic use , Malaria*/drug therapy , Malaria, Falciparum*/drug therapy , Malaria, Falciparum*/epidemiology , Malaria, Falciparum*/prevention & control , Pharmaceutical Preparations*, Drug Resistance/genetics ; Humans ; Plasmodium falciparum/genetics
مستخلص: The use of antimalarial drugs is an effective strategy in the fight against malaria. However, selection of drug resistant parasites is a constant threat to the continued use of this approach. Antimalarial drugs are used not only to treat infections but also as part of population-level strategies to reduce malaria transmission toward elimination. While there is strong evidence that the ongoing use of antimalarial drugs increases the risk of the emergence and spread of drug-resistant parasites, it is less clear how population-level use of drug-based interventions like seasonal malaria chemoprevention (SMC) or mass drug administration (MDA) may contribute to drug resistance or loss of drug efficacy. Critical to sustained use of drug-based strategies for reducing the burden of malaria is the surveillance of population-level signals related to transmission reduction and resistance selection. Here we focus on Plasmodium falciparum and discuss the genetic signatures of a parasite population that are correlated with changes in transmission and related to drug pressure and resistance as a result of drug use. We review the evidence for MDA and SMC contributing to malaria burden reduction and drug resistance selection and examine the use and impact of these interventions in Senegal. Throughout we consider best strategies for ongoing surveillance of both population and resistance signals in the context of different parasite population parameters. Finally, we propose a roadmap for ongoing surveillance during population-level drug-based interventions to reduce the global malaria burden.
(Copyright © 2021. Published by Elsevier Ltd.)
References: Mol Microbiol. 2013 Sep;89(6):1025-38. (PMID: 23899091)
J Infect Dis. 2022 Apr 1;225(7):1227-1237. (PMID: 32840625)
Proc Biol Sci. 2012 Jul 7;279(1738):2589-98. (PMID: 22398165)
Trends Parasitol. 2003 Oct;19(10):452-60. (PMID: 14519583)
BMJ Glob Health. 2020 Jun;5(6):. (PMID: 32601091)
Am J Trop Med Hyg. 2015 Jul;93(1):125-134. (PMID: 26013371)
BMC Infect Dis. 2017 Sep 13;17(1):621. (PMID: 28903726)
Genome Med. 2017 Jan 24;9(1):5. (PMID: 28118860)
Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12025-30. (PMID: 19587242)
Genetics. 2019 Aug;212(4):1337-1351. (PMID: 31209105)
Infect Drug Resist. 2018 Mar 01;11:299-306. (PMID: 29535546)
Lancet Infect Dis. 2017 Feb;17(2):174-183. (PMID: 27818097)
Antimicrob Agents Chemother. 2014 Jul;58(7):3660-5. (PMID: 24733476)
PLoS One. 2012;7(2):e32891. (PMID: 22393456)
Lancet. 2020 Dec 5;396(10265):1829-1840. (PMID: 33278936)
Clin Microbiol Rev. 2019 Jul 31;32(4):. (PMID: 31366610)
Gene. 1989 Mar 15;76(1):41-52. (PMID: 2663650)
Malar J. 2019 May 7;18(1):163. (PMID: 31064369)
Cold Spring Harb Perspect Med. 2017 Jul 5;7(7):. (PMID: 28289248)
Sci Rep. 2016 May 19;6:26370. (PMID: 27193195)
Mol Cell. 2000 Oct;6(4):861-71. (PMID: 11090624)
PLoS Comput Biol. 2018 Jan 9;14(1):e1005923. (PMID: 29315306)
PLoS One. 2016 Sep 23;11(9):e0162718. (PMID: 27662368)
Lancet Infect Dis. 2017 Feb;17(2):164-173. (PMID: 27818095)
Sci Rep. 2018 May 29;8(1):8286. (PMID: 29844487)
PLoS Med. 2011 Jan 25;8(1):e1000403. (PMID: 21283605)
Bioinformatics. 2018 Jan 1;34(1):9-15. (PMID: 28961721)
Lancet Glob Health. 2020 Dec;8(12):e1499-e1511. (PMID: 33222799)
Am J Trop Med Hyg. 2016 Jan;94(1):143-6. (PMID: 26503281)
PLoS Pathog. 2020 Dec 15;16(12):e1009133. (PMID: 33320907)
Proc Natl Acad Sci U S A. 1988 Dec;85(23):9114-8. (PMID: 2904149)
Gene. 2020 Apr 30;736:144414. (PMID: 32006594)
Malar J. 2019 Jul 1;18(1):219. (PMID: 31262308)
Lancet Infect Dis. 2017 Jun;17(6):588. (PMID: 28555586)
PLoS Comput Biol. 2017 Jan 26;13(1):e1005348. (PMID: 28125584)
Genet Res. 1995 Feb;65(1):53-61. (PMID: 7750746)
J Infect Dis. 2018 Aug 14;218(6):946-955. (PMID: 29718283)
Sci Rep. 2018 Jul 5;8(1):10159. (PMID: 29977002)
PLoS Genet. 2020 Dec 31;16(12):e1009268. (PMID: 33382691)
Mol Biol Evol. 2017 Jan;34(1):131-144. (PMID: 28025270)
PLoS Med. 2016 Nov 22;13(11):e1002175. (PMID: 27875528)
Cell Host Microbe. 2019 Jul 10;26(1):35-47. (PMID: 31295423)
Lancet Child Adolesc Health. 2020 Oct;4(10):775-789. (PMID: 32946831)
Malar J. 2017 Jun 14;16(1):250. (PMID: 28615016)
PLoS Med. 2017 Nov 30;14(11):e1002453. (PMID: 29190295)
Nat Commun. 2020 Apr 30;11(1):2107. (PMID: 32355199)
Nature. 2014 Jan 2;505(7481):50-5. (PMID: 24352242)
Cold Spring Harb Perspect Med. 2017 Aug 1;7(8):. (PMID: 28389516)
PLoS Genet. 2018 May 23;14(5):e1007279. (PMID: 29791438)
PLoS One. 2020 Oct 19;15(10):e0240174. (PMID: 33075062)
Trends Parasitol. 2020 Nov;36(11):906-913. (PMID: 32917511)
Lancet Infect Dis. 2019 May;19(5):546-556. (PMID: 30922818)
Lancet Infect Dis. 2017 Feb;17(2):184-193. (PMID: 27865890)
Malar J. 2018 May 29;17(1):217. (PMID: 29843734)
Mol Biochem Parasitol. 1993 Jan;57(1):151-60. (PMID: 8426608)
Trends Parasitol. 2021 Jan;37(1):15-24. (PMID: 33060063)
mBio. 2019 Apr 30;10(2):. (PMID: 31040246)
Mol Biol Evol. 2021 Jan 4;38(1):274-289. (PMID: 32898225)
Lancet. 2004 Jul 31-Aug 6;364(9432):438-447. (PMID: 15288742)
Clin Infect Dis. 2018 Nov 13;67(11):1670-1676. (PMID: 29846536)
BMC Genomics. 2017 Nov 13;18(1):864. (PMID: 29132317)
Lancet Infect Dis. 2018 Mar;18(3):337-345. (PMID: 29398391)
Proc Natl Acad Sci U S A. 2015 Jun 2;112(22):7067-72. (PMID: 25941365)
BMJ Glob Health. 2018 Oct 19;3(5):e000999. (PMID: 30397515)
Nat Commun. 2018 May 2;9(1):1769. (PMID: 29720620)
Antimicrob Agents Chemother. 2000 Aug;44(8):2100-8. (PMID: 10898682)
Malar J. 2017 Apr 19;16(1):153. (PMID: 28420422)
Malar J. 2020 Mar 30;19(1):134. (PMID: 32228566)
Mol Biol Evol. 2007 Feb;24(2):562-73. (PMID: 17124182)
Antimicrob Agents Chemother. 2007 Feb;51(2):521-7. (PMID: 17116685)
Malar J. 2017 May 12;16(1):195. (PMID: 28494763)
PLoS Med. 2019 Mar 13;16(3):e1002762. (PMID: 30865632)
Genetics. 2017 Apr;205(4):1573-1586. (PMID: 28213477)
Elife. 2019 Jul 12;8:. (PMID: 31298657)
Trends Ecol Evol. 2013 Nov;28(11):659-69. (PMID: 24075201)
Genetics. 2005 Apr;169(4):2335-52. (PMID: 15716498)
PLoS Genet. 2017 Oct 27;13(10):e1007065. (PMID: 29077712)
Elife. 2016 Mar 04;5:. (PMID: 26943619)
PLoS One. 2018 Sep 20;13(9):e0204347. (PMID: 30235327)
Sci Rep. 2019 Nov 28;9(1):17790. (PMID: 31780741)
Brief Funct Genomics. 2019 Sep 24;18(5):314-328. (PMID: 31119263)
Res Rep Trop Med. 2020 Sep 17;11:61-72. (PMID: 32982538)
Malar J. 2016 Dec 5;15(1):584. (PMID: 27919256)
Am J Trop Med Hyg. 2016 Nov 2;95(5):1054-1060. (PMID: 27549635)
Adv Parasitol. 2014;84:151-208. (PMID: 24480314)
Nat Commun. 2019 Jun 17;10(1):2665. (PMID: 31209259)
N Engl J Med. 2006 Nov 9;355(19):1959-66. (PMID: 17093247)
Cell Host Microbe. 2020 Jan 8;27(1):93-103.e4. (PMID: 31901523)
Cochrane Database Syst Rev. 2012 Feb 15;(2):CD003756. (PMID: 22336792)
Bull World Health Organ. 1995;73(1):85-95. (PMID: 7704931)
Malar J. 2020 Jan 28;19(1):47. (PMID: 31992305)
J Infect Dis. 2016 May 1;213(9):1472-5. (PMID: 26690347)
Genes (Basel). 2019 Jul 16;10(7):. (PMID: 31315304)
Trends Parasitol. 2018 Apr;34(4):322-334. (PMID: 29396203)
BMC Med. 2018 Oct 18;16(1):190. (PMID: 30333020)
Annu Rev Microbiol. 2020 Sep 8;74:761-786. (PMID: 32905749)
Genome Res. 2014 Jun;24(6):1028-38. (PMID: 24812326)
Genome Biol Evol. 2017 Dec 1;9(12):3373-3383. (PMID: 29220419)
Lancet. 2018 May 12;391(10133):1916-1926. (PMID: 29703425)
J Infect. 2017 Jun;74 Suppl 1:S23-S26. (PMID: 28646958)
Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):12799-12804. (PMID: 30420498)
Genetics. 1989 Dec;123(4):887-99. (PMID: 2612899)
Malar J. 2019 Dec 4;18(1):400. (PMID: 31801548)
Nat Rev Genet. 2012 Apr 12;13(5):315-28. (PMID: 22495435)
Malar J. 2018 Feb 08;17(1):75. (PMID: 29422048)
Antimicrob Agents Chemother. 2019 Aug 23;63(9):. (PMID: 31307982)
Malar J. 2015 Jan 19;14:4. (PMID: 25599890)
Elife. 2020 May 12;9:. (PMID: 32394893)
J Infect Dis. 2014 Oct 1;210(7):1110-4. (PMID: 24723474)
PLoS Comput Biol. 2021 Aug 19;17(8):e1009287. (PMID: 34411093)
Malar J. 2018 May 15;17(1):196. (PMID: 29764422)
Lancet Infect Dis. 2015 Apr;15(4):415-21. (PMID: 25704894)
Nature. 2002 Jul 18;418(6895):320-3. (PMID: 12124623)
Infect Immun. 2001 Dec;69(12):7783-92. (PMID: 11705960)
Emerg Infect Dis. 2014 Jun;20(6):932-40. (PMID: 24856348)
Malar J. 2019 Aug 22;18(1):281. (PMID: 31438950)
PLoS Genet. 2020 Nov 16;16(11):e1009101. (PMID: 33196661)
Genet Res. 1974 Feb;23(1):23-35. (PMID: 4407212)
Cochrane Database Syst Rev. 2013 Dec 09;(12):CD008846. (PMID: 24318836)
Malar J. 2016 Sep 15;15:473. (PMID: 27634595)
Science. 2019 Aug 23;365(6455):813-816. (PMID: 31439796)
Science. 2004 Aug 20;305(5687):1124. (PMID: 15326348)
Malar J. 2017 Dec 16;16(1):490. (PMID: 29246158)
Am J Trop Med Hyg. 2020 Aug;103(2_Suppl):66-73. (PMID: 32618255)
Malar J. 2016 Aug 25;15(1):433. (PMID: 27562216)
Infect Genet Evol. 2018 Nov;65:414-424. (PMID: 30145390)
J R Soc Interface. 2015 Mar 6;12(104):20141379. (PMID: 25673299)
J Clin Invest. 2009 Sep;119(9):2496-505. (PMID: 19729847)
معلومات مُعتمدة: INV-003442 United States GATES Bill & Melinda Gates Foundation; INV-004036 United States GATES Bill & Melinda Gates Foundation; R01 AI099105 United States AI NIAID NIH HHS
فهرسة مساهمة: Keywords: Genetic surveillance; Mass drug administration (MDA); Population genetics; Seasonal malaria chemoprevention (SMC); Selective sweep; Therapeutic efficacy study (TES)
المشرفين على المادة: 0 (Antimalarials)
0 (Pharmaceutical Preparations)
تواريخ الأحداث: Date Created: 20210801 Date Completed: 20220106 Latest Revision: 20240404
رمز التحديث: 20240404
مُعرف محوري في PubMed: PMC8342550
DOI: 10.1016/j.ijpddr.2021.07.004
PMID: 34333350
قاعدة البيانات: MEDLINE
الوصف
تدمد:2211-3207
DOI:10.1016/j.ijpddr.2021.07.004